Publications by authors named "D Maruyama"
Article Synopsis
- * New treatment options include targeted drugs like antibody-drug conjugates and small molecules, as well as immune therapies such as CAR T cell therapy and bispecific antibodies, altering how DLBCL and FL are approached therapeutically.
- * Currently, treatment choices are primarily based on factors like patient history, age, and response to previous therapies rather than randomized trials or a standardized prognostic index, highlighting a need for more comprehensive treatment strategies and future research in this area
Article Synopsis
- Researchers are testing valemetostat, an EZH2 and EZH1 inhibitor, for safety and effectiveness in patients with relapsed or refractory non-Hodgkin lymphoma, due to limited treatment options and poor outcomes.
- The study involved 90 participants from 19 hospitals across Japan and the USA, who received varying doses of valemetostat in a phase 1 clinical trial to find the right dosage and assess its anti-tumor effects.
- Initial findings will help determine the most effective dosages and provide insights into the drug's safety profile, with a majority of patients having peripheral T-cell lymphoma.
Article Synopsis
- * The study is a phase III trial testing whether high-dose therapy with autologous stem cell transplantation improves progression-free survival over simply observing patients who have responded well to initial treatment.
- * A total of 140 patients will participate from 52 hospitals in Japan over a period of 5.5 years, and the trial is officially registered in the Japan Registry of Clinical Trials.
[Current standard treatments and future outlook for follicular lymphoma].
Rinsho Ketsueki
October 2024
Article Synopsis
- * For patients with limited-stage FL, radiation therapy is preferred and can result in nearly 20 years of median survival, whereas advanced-stage patients with low tumor burden may benefit from a strategy of careful monitoring (watchful waiting).
- * Advanced-stage patients with high tumor burden typically receive chemoimmunotherapy, while various treatments are being explored for relapsed cases, including new therapies like CAR T-cell and bispecific antibodies.